MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) — SAB BIO SABS (the “Firm” or “SAB”), a clinical-stage biopharmaceutical firm with a novel immunotherapy platform growing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or development of T1D, as we speak introduced that Chairman and CEO Samuel J. Reich will likely be collaborating in a hearth chat on the 2024 Cantor International Healthcare Convention, September 17-19th, 2024.
Hearth Chat: September 18th, 2024, at 8:00 am ET
Location: New York, NY
Webcast Registration Hyperlink: Here
A recording of the webcast will likely be accessible by way of the “Occasions” part of the Firm’s web site at https://ir.sab.bio/news-events/events.
About SAB BIO
SAB BIO (SAB) is a clinical-stage biopharmaceutical firm centered on growing human, multi- focused, high-potency immunoglobulins (IgGs), with out the necessity for human donors or convalescent plasma, to deal with and forestall immune and autoimmune problems. The Firm’s lead asset, SAB-142, targets T1D with a disease-modifying therapeutic method that goals to vary the remedy paradigm by delaying onset and probably stopping illness development. Utilizing superior genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine™, the one transgenic animal with a human synthetic chromosome, SAB’s DiversitAb™ drug growth manufacturing system is ready to generate a various repertoire of particularly focused, high-potency, human IgGs that may tackle a variety of significant unmet wants in human ailments with out the necessity for convalescent plasma or human donors. For extra data on SAB, go to: www.SAB.bio and observe SAB on LinkedIn.
Ahead-Wanting Statements
Sure statements made on this present report that aren’t historic info are forward-looking statements for functions of the secure harbor provisions underneath The Personal Securities Litigation Reform Act of 1995. Ahead-looking statements typically are accompanied by phrases reminiscent of “consider,” “could,” “will,” “to be,” “estimate,” “proceed,” “anticipate,” “intend,” “count on,” “ought to,” “would,” “plan,” “predict,” “potential,” “appear,” “search,” “future,” “outlook,” and comparable expressions that predict or point out future occasions or developments or that aren’t statements of historic issues. These forward-looking statements embrace, however usually are not restricted to, statements concerning future occasions, together with, the event and efficacy of our T1D program and different discovery applications.
These statements are primarily based on the present expectations of SAB and usually are not predictions of precise efficiency, and usually are not supposed to function, and should not be relied on, by any investor as a assure, prediction, definitive assertion, or an assurance, of truth or likelihood. These statements are solely present predictions or expectations, and are topic to recognized and unknown dangers, uncertainties and different components which can be past our management. Precise occasions and circumstances are tough or unattainable to foretell, and these dangers and uncertainties could trigger our or our trade’s outcomes, efficiency, or achievements to be materially completely different from these anticipated by these forward-looking statements. An additional description of dangers and uncertainties will be discovered within the sections captioned “Threat Elements” in our most up-to-date annual report on Type 10-Okay, subsequent quarterly reviews on Type 10-Q, as could also be amended or supplemented sometimes, and different filings with or submissions to, the U.S. Securities and Trade Fee, which can be found at https://www.sec.gov/. Besides as in any other case required by legislation, SAB disclaims any intention or obligation to replace or revise any forward-looking statements, which communicate solely as of the date they had been made, whether or not because of new data, future occasions, or circumstances or in any other case.
CONTACTS
Media Relations:
Kaelan Hollon
[email protected]
Investor Relations:
Kevin Gardner
LifeSci Advisors
[email protected]
Chris Calabrese
LifeSci Advisors
[email protected]
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
